董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anne C. Whitaker | 女 | Director | 54 | 未披露 | 未持股 | 2022-04-21 |
| Gregory B. Brown | 男 | Chairman | 68 | 15.85万美元 | 未持股 | 2022-04-21 |
| Cynthia L. Flowers | 女 | Director | 62 | 11.25万美元 | 未持股 | 2022-04-21 |
| David J. Mazzo | 男 | Director,President and Chief Executive Officer | 65 | 133.52万美元 | 未持股 | 2022-04-21 |
| Steven S. Myers | 男 | Director | 75 | 12.30万美元 | 未持股 | 2022-04-21 |
| Steven M. Klosk | 男 | Director | 65 | 12.45万美元 | 未持股 | 2022-04-21 |
| Peter G. Traber | 男 | Director | 66 | 10.90万美元 | 未持股 | 2022-04-21 |
| Michael H. Davidson | 男 | Director | 65 | 11.35万美元 | 未持股 | 2022-04-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Todd C. Girolamo | 男 | Senior Vice President, General Counsel and Corporate Secretary | 57 | 未披露 | 未持股 | 2022-04-21 |
| Kristen K. Buck | 女 | Executive Vice President R,D and Chief Medical Officer | 48 | 185.83万美元 | 未持股 | 2022-04-21 |
| David J. Mazzo | 男 | Director,President and Chief Executive Officer | 65 | 133.52万美元 | 未持股 | 2022-04-21 |
董事简历
中英对照 | 中文 | 英文- Anne C. Whitaker
-
Anne C. Whitaker，2013年1月，她上市生物制药公司加入董事会。2014年9月起，她担任Synta Pharmaceuticals Corp.的首席执行官、总裁和董事会成员。2011年9月至2014年8月，她担任Sanofi S.A.的北美制药总裁， 该公司是全球综合医疗保健领导公司，专注患者需求。2009年9月至2011年9月，她担任上市要去研发公司GlaxoSmithKline plc的高级副总裁和心血管、新陈代谢和泌尿业务单元主管。2008年10月至2009年8月，她担任领导与组织发展高级副总裁，在此之前，在GlaxoSmithKline担任多职。1991年，她在Upjohn Company担任新陈代谢疾病专家，开始职业生涯，1992年加入GlaxoSmithKline担任销售代表。
Anne C. Whitaker became a member of the Board in November 2021 and serves on the Audit Committee. Ms. Whitaker is a seasoned healthcare executive and director with more than 30 years of experience and a proven track record as an executive of building and leading high-performance teams. Ms. Whitaker currently serves as Managing Partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, and is the current Chairperson of the Board of Aerami Therapeutics, a private life science company. Prior to taking the Chair role at Aerami, she served as the CEO from October 2018 to November 2020 and as a director from July 2018. She also serves as an independent director on the boards of three public companies including Faron Pharmaceuticals, a development stage pharma company; Caladrius, a development stage biotech company; and Mallinckrodt, a specialty pharmaceutical company. In addition to her board work, she is an active industry advisor to private equity and venture capital funds in the U.S. and Europe. Ms. Whitaker started her healthcare career with The Upjohn Company selling pharmaceuticals. She subsequently transitioned to GlaxoSmithKline PLC, where she spent 19 years and rose in the commercial ranks from a sales representative to become a Senior Vice President, Business Unit Head for the Cardiovascular, Metabolic, and Urology franchises in 2009. She joined Sanofi SA in 2011 as the President of the North America Pharmaceutical Region. Anne served as the CEO and President of Synta Pharmaceuticals, Inc. in 2014 and 2015. She joined Bausch Health as an Executive Vice President and Company Group Chairman for the Branded Pharmaceuticals segment in mid-2015. From February 2017 until April 2018 she served as the CEO and President of Novoclem Therapeutics, Inc. Ms. Whitaker holds a Bachelor of Science degree in chemistry from the University of North Alabama. - Anne C. Whitaker，2013年1月，她上市生物制药公司加入董事会。2014年9月起，她担任Synta Pharmaceuticals Corp.的首席执行官、总裁和董事会成员。2011年9月至2014年8月，她担任Sanofi S.A.的北美制药总裁， 该公司是全球综合医疗保健领导公司，专注患者需求。2009年9月至2011年9月，她担任上市要去研发公司GlaxoSmithKline plc的高级副总裁和心血管、新陈代谢和泌尿业务单元主管。2008年10月至2009年8月，她担任领导与组织发展高级副总裁，在此之前，在GlaxoSmithKline担任多职。1991年，她在Upjohn Company担任新陈代谢疾病专家，开始职业生涯，1992年加入GlaxoSmithKline担任销售代表。
- Anne C. Whitaker became a member of the Board in November 2021 and serves on the Audit Committee. Ms. Whitaker is a seasoned healthcare executive and director with more than 30 years of experience and a proven track record as an executive of building and leading high-performance teams. Ms. Whitaker currently serves as Managing Partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, and is the current Chairperson of the Board of Aerami Therapeutics, a private life science company. Prior to taking the Chair role at Aerami, she served as the CEO from October 2018 to November 2020 and as a director from July 2018. She also serves as an independent director on the boards of three public companies including Faron Pharmaceuticals, a development stage pharma company; Caladrius, a development stage biotech company; and Mallinckrodt, a specialty pharmaceutical company. In addition to her board work, she is an active industry advisor to private equity and venture capital funds in the U.S. and Europe. Ms. Whitaker started her healthcare career with The Upjohn Company selling pharmaceuticals. She subsequently transitioned to GlaxoSmithKline PLC, where she spent 19 years and rose in the commercial ranks from a sales representative to become a Senior Vice President, Business Unit Head for the Cardiovascular, Metabolic, and Urology franchises in 2009. She joined Sanofi SA in 2011 as the President of the North America Pharmaceutical Region. Anne served as the CEO and President of Synta Pharmaceuticals, Inc. in 2014 and 2015. She joined Bausch Health as an Executive Vice President and Company Group Chairman for the Branded Pharmaceuticals segment in mid-2015. From February 2017 until April 2018 she served as the CEO and President of Novoclem Therapeutics, Inc. Ms. Whitaker holds a Bachelor of Science degree in chemistry from the University of North Alabama.
- Gregory B. Brown
-
Gregory B. Brown，自2014年2月起担任公司董事；自2015年3月起担任公司董事长。Brown自2007年10月起担任HealthCare Royalty Partners（一家医疗保健投资公司）创始管理董事。联合创立HealthCare Royalty Partners之前，Brown从2002年到2007年担任Paul Capital Partners（一家投资公司）合伙人。Brown从1997年到2002年担任Adams, Harkness & Hill 现名为Canaccord Genuity投资银行联合主管和医疗保健主管；1992年到1997年担任Vector Securities International生物技术研究分析师和投资银行家。在此之前，Brown一直担任胸和血管外科医生。Brown持有Yale University文学学士学位；SUNY Upstate Medical Center文学硕士学位；Harvard Business School工商管理硕士学位。
Gregory B. Brown was appointed to the Caladrius Board in October 2016 and was elected Chairman by the Caladrius Board on February 16 2017. Dr. Brown is currently Chief Executive Officer of Memgen, Inc., a development-stage biotechnology company. In 2007 Dr. Brown co-founded HealthCare Royalty Partners "HCR Partners", a healthcare-focused private asset management firm investing in biopharmaceutical and medical products, and developing and deploying innovative risk-mitigated investment strategies to deliver non-correlated cash flow. Dr. Brown remains Vice Chairman of HCR Partners and a member of the firm's SAB. Dr. Brown was educated as a transplantation immunologist and trained as a thoracic and vascular surgeon. He practiced thoracic and vascular surgery in a community setting where he also founded and led a health maintenance organization. He has been involved in sourcing, performing due diligence on and closing more than $1 billion of royalty financings.Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners where he co-managed that firm's royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003 Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center and an M.B.A. from Harvard Business School. He currently serves on the boards of FAST Biomedical since January 2020 Memgen, Inc. since October 2018 Aquestive Therapeutics, Inc. since 2007 and Faron Pharmaceuticals, Oy since 2017. He previously served on the boards of Cambrex Corporation, Invuity, Inc. and Vanderbilt Clinical, S.a.r.l. - Gregory B. Brown，自2014年2月起担任公司董事；自2015年3月起担任公司董事长。Brown自2007年10月起担任HealthCare Royalty Partners（一家医疗保健投资公司）创始管理董事。联合创立HealthCare Royalty Partners之前，Brown从2002年到2007年担任Paul Capital Partners（一家投资公司）合伙人。Brown从1997年到2002年担任Adams, Harkness & Hill 现名为Canaccord Genuity投资银行联合主管和医疗保健主管；1992年到1997年担任Vector Securities International生物技术研究分析师和投资银行家。在此之前，Brown一直担任胸和血管外科医生。Brown持有Yale University文学学士学位；SUNY Upstate Medical Center文学硕士学位；Harvard Business School工商管理硕士学位。
- Gregory B. Brown was appointed to the Caladrius Board in October 2016 and was elected Chairman by the Caladrius Board on February 16 2017. Dr. Brown is currently Chief Executive Officer of Memgen, Inc., a development-stage biotechnology company. In 2007 Dr. Brown co-founded HealthCare Royalty Partners "HCR Partners", a healthcare-focused private asset management firm investing in biopharmaceutical and medical products, and developing and deploying innovative risk-mitigated investment strategies to deliver non-correlated cash flow. Dr. Brown remains Vice Chairman of HCR Partners and a member of the firm's SAB. Dr. Brown was educated as a transplantation immunologist and trained as a thoracic and vascular surgeon. He practiced thoracic and vascular surgery in a community setting where he also founded and led a health maintenance organization. He has been involved in sourcing, performing due diligence on and closing more than $1 billion of royalty financings.Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners where he co-managed that firm's royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003 Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center and an M.B.A. from Harvard Business School. He currently serves on the boards of FAST Biomedical since January 2020 Memgen, Inc. since October 2018 Aquestive Therapeutics, Inc. since 2007 and Faron Pharmaceuticals, Oy since 2017. He previously served on the boards of Cambrex Corporation, Invuity, Inc. and Vanderbilt Clinical, S.a.r.l.
- Cynthia L. Flowers
-
Cynthia L. Flowers于2018年11月被任命为Caladrius董事会成员。她是生命科学咨询和战略投资公司EIR Advisory LLC的所有者。从2014年2月到2017年11月，Flowers女士担任Ipsen North America的总裁兼首席执行官，在那里她领导了公司的转型，使其成为全球增长最快的子公司。在加入Ipsen之前，她曾担任卫材制药总裁，负责监督商业运营、医疗事务和服务、制造、联盟管理和其他职能。她还曾在安进公司和强生公司公司担任过国内和国际的综合管理职务。Flowers女士的职业生涯始于肿瘤学/重症监护护士。Flowers目前在多代仿制药公司Hikma Pharmaceuticals plc和生物技术临床开发公司G1 Therapeutics Inc.的董事会任职。她曾在众多公司和非营利董事会任职，包括纳米颗粒制造公司Nanoform Finland OYI、临床阶段生物制药公司Kadmon Group，Inc.、哈佛大学John F. Kennedy政府学院的女性领导咨询委员会和Sarah Cannon肿瘤研究所的董事会。她目前担任沃顿商学院领导力顾问。Flowers女士拥有宾夕法尼亚大学沃顿商学院的工商管理硕士学位和理学学士学位。来自特拉华大学。
Cynthia L. Flowers was appointed to the Caladrius Board in November 2018. She is the owner of EIR Advisory LLC, a life sciences advisory and strategic investment firm. From February 2014 through November 2017 Ms. Flowers was President and Chief Executive Officer of Ipsen North America, where she led the transformation of the company as it became the highest-growth subsidiary worldwide. Prior to joining Ipsen, she served as President of Eisai Pharmaceuticals, where she oversaw commercial operations, medical affairs and services, manufacturing, alliance management and other functions. She has also held general management roles, both domestically and internationally, at Amgen Inc. and Johnson & Johnson. Ms. Flowers began her career as an oncology/critical care nurse.Ms. Flowers currently serves on the board of Hikma Pharmaceuticals PLC, a multigenerational generics company and G1 Therapeutics Inc., a biotechnology clinical development company. She has held positions on numerous corporate and non-profit boards, including Nanoform Finland OYi, a nanoparticle manufacturing company, Kadmon Group, Inc., a clinical stage biopharmaceutical company, the Women's Leadership Advisory Board for the John F. Kennedy School of Government at Harvard University and the board of directors for the Sarah Cannon Oncology Research Institute. She currently serves as a Wharton Business School Leadership Advisor. Ms. Flowers holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S.N. from the University of Delaware. - Cynthia L. Flowers于2018年11月被任命为Caladrius董事会成员。她是生命科学咨询和战略投资公司EIR Advisory LLC的所有者。从2014年2月到2017年11月，Flowers女士担任Ipsen North America的总裁兼首席执行官，在那里她领导了公司的转型，使其成为全球增长最快的子公司。在加入Ipsen之前，她曾担任卫材制药总裁，负责监督商业运营、医疗事务和服务、制造、联盟管理和其他职能。她还曾在安进公司和强生公司公司担任过国内和国际的综合管理职务。Flowers女士的职业生涯始于肿瘤学/重症监护护士。Flowers目前在多代仿制药公司Hikma Pharmaceuticals plc和生物技术临床开发公司G1 Therapeutics Inc.的董事会任职。她曾在众多公司和非营利董事会任职，包括纳米颗粒制造公司Nanoform Finland OYI、临床阶段生物制药公司Kadmon Group，Inc.、哈佛大学John F. Kennedy政府学院的女性领导咨询委员会和Sarah Cannon肿瘤研究所的董事会。她目前担任沃顿商学院领导力顾问。Flowers女士拥有宾夕法尼亚大学沃顿商学院的工商管理硕士学位和理学学士学位。来自特拉华大学。
- Cynthia L. Flowers was appointed to the Caladrius Board in November 2018. She is the owner of EIR Advisory LLC, a life sciences advisory and strategic investment firm. From February 2014 through November 2017 Ms. Flowers was President and Chief Executive Officer of Ipsen North America, where she led the transformation of the company as it became the highest-growth subsidiary worldwide. Prior to joining Ipsen, she served as President of Eisai Pharmaceuticals, where she oversaw commercial operations, medical affairs and services, manufacturing, alliance management and other functions. She has also held general management roles, both domestically and internationally, at Amgen Inc. and Johnson & Johnson. Ms. Flowers began her career as an oncology/critical care nurse.Ms. Flowers currently serves on the board of Hikma Pharmaceuticals PLC, a multigenerational generics company and G1 Therapeutics Inc., a biotechnology clinical development company. She has held positions on numerous corporate and non-profit boards, including Nanoform Finland OYi, a nanoparticle manufacturing company, Kadmon Group, Inc., a clinical stage biopharmaceutical company, the Women's Leadership Advisory Board for the John F. Kennedy School of Government at Harvard University and the board of directors for the Sarah Cannon Oncology Research Institute. She currently serves as a Wharton Business School Leadership Advisor. Ms. Flowers holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S.N. from the University of Delaware.
- David J. Mazzo
-
David J. Mazzo， 从2008年8月起担任公司CEO和董事会成员。他在制药行业有将近30年经验。2007年3月-2008年4月，他担任terna Zentaris--一家上市国际生物制药公司的总裁、CEO兼董事。2003-2007年，他担任美国Chugai制药公司总裁、CEO兼董事，Chugai是一家生物制药公司，是日本Chugai制药公司的美国子公司。他也担任过研发部高级管理和行政职位，曾是艾塞克斯奇美欧洲子公司先灵葆雅公司董事，先灵葆雅是一家上市制药公司，后被默克公司收购；Hoechst Marion Roussel公司是Hoechst公司的美国子公司，后被赛诺菲制药集团收购，赛诺菲是一家跨国制药公司； Rhone-Poulenc Rorer公司是Rhone-Poulene SA子公司，后者是一家法国制药公司，后来被Hoechst AG公司收购。他目前在pSivida公司--上市生物科技公司的董事会任职，担任非执行董事长；也在Avanir 制药公司--上市生物科技公司的董事会任职。他拥有荣誉项目跨学科人文学士学位和维纳诺瓦大学化学学士学位。另外，他还拥有艾摩斯特马萨诸塞大学化学硕士和分析化学博士学位。他同时也是瑞士洛桑巴黎理工大学的一名研究人员。
David J. Mazzo was appointed as Caladrius' President and Chief Executive Officer on March 28 2017. Dr. Mazzo was previously appointed as Caladrius' Chief Executive Officer and as a member of the Caladrius Board on January 5 2015. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. Nasdaq: RGDO, a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a director of terna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and director of Chugai Pharma USA, LLC, a biopharmaceutical company and U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, that was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, that was subsequently acquired by Hoechst AG. He previously served on the board of directors of publicly held EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.), a biopharmaceutical company, from October 2005 to June 2020 Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA), a therapeutics development company focused on CNS applications that merged with Palisade BIO, from April 2019 to April 2021 and Avanir Pharmaceuticals, Inc., from October 2005 through January 2015 a pharmaceutical company that was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc. (ASX: VTI), a developer and seller of therapeutic contact lenses, where he has served as Chairman of the board since February 2020 and Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents, where he has served on the board since January 2021.Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.David J. Mazzo was appointed as Caladrius' President and Chief Executive Officer on March 28 2017. Dr. Mazzo was previously appointed as Caladrius' Chief Executive Officer and as a member of the Caladrius Board on January 5 2015. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. Nasdaq: RGDO, a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a director of terna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and director of Chugai Pharma USA, LLC, a biopharmaceutical company and U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, that was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, that was subsequently acquired by Hoechst AG. He previously served on the board of directors of publicly held EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.), a biopharmaceutical company, from October 2005 to June 2020 Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA), a therapeutics development company focused on CNS applications that merged with Palisade BIO, from April 2019 to April 2021 and Avanir Pharmaceuticals, Inc., from October 2005 through January 2015 a pharmaceutical company that was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc. (ASX: VTI), a developer and seller of therapeutic contact lenses, where he has served as Chairman of the board since February 2020 and Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents, where he has served on the board since January 2021.Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland. - David J. Mazzo， 从2008年8月起担任公司CEO和董事会成员。他在制药行业有将近30年经验。2007年3月-2008年4月，他担任terna Zentaris--一家上市国际生物制药公司的总裁、CEO兼董事。2003-2007年，他担任美国Chugai制药公司总裁、CEO兼董事，Chugai是一家生物制药公司，是日本Chugai制药公司的美国子公司。他也担任过研发部高级管理和行政职位，曾是艾塞克斯奇美欧洲子公司先灵葆雅公司董事，先灵葆雅是一家上市制药公司，后被默克公司收购；Hoechst Marion Roussel公司是Hoechst公司的美国子公司，后被赛诺菲制药集团收购，赛诺菲是一家跨国制药公司； Rhone-Poulenc Rorer公司是Rhone-Poulene SA子公司，后者是一家法国制药公司，后来被Hoechst AG公司收购。他目前在pSivida公司--上市生物科技公司的董事会任职，担任非执行董事长；也在Avanir 制药公司--上市生物科技公司的董事会任职。他拥有荣誉项目跨学科人文学士学位和维纳诺瓦大学化学学士学位。另外，他还拥有艾摩斯特马萨诸塞大学化学硕士和分析化学博士学位。他同时也是瑞士洛桑巴黎理工大学的一名研究人员。
- David J. Mazzo was appointed as Caladrius' President and Chief Executive Officer on March 28 2017. Dr. Mazzo was previously appointed as Caladrius' Chief Executive Officer and as a member of the Caladrius Board on January 5 2015. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. Nasdaq: RGDO, a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a director of terna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and director of Chugai Pharma USA, LLC, a biopharmaceutical company and U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, that was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, that was subsequently acquired by Hoechst AG. He previously served on the board of directors of publicly held EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.), a biopharmaceutical company, from October 2005 to June 2020 Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA), a therapeutics development company focused on CNS applications that merged with Palisade BIO, from April 2019 to April 2021 and Avanir Pharmaceuticals, Inc., from October 2005 through January 2015 a pharmaceutical company that was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc. (ASX: VTI), a developer and seller of therapeutic contact lenses, where he has served as Chairman of the board since February 2020 and Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents, where he has served on the board since January 2021.Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.David J. Mazzo was appointed as Caladrius' President and Chief Executive Officer on March 28 2017. Dr. Mazzo was previously appointed as Caladrius' Chief Executive Officer and as a member of the Caladrius Board on January 5 2015. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. Nasdaq: RGDO, a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a director of terna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and director of Chugai Pharma USA, LLC, a biopharmaceutical company and U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, that was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, that was subsequently acquired by Hoechst AG. He previously served on the board of directors of publicly held EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.), a biopharmaceutical company, from October 2005 to June 2020 Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA), a therapeutics development company focused on CNS applications that merged with Palisade BIO, from April 2019 to April 2021 and Avanir Pharmaceuticals, Inc., from October 2005 through January 2015 a pharmaceutical company that was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc. (ASX: VTI), a developer and seller of therapeutic contact lenses, where he has served as Chairman of the board since February 2020 and Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents, where he has served on the board since January 2021.Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.
- Steven S. Myers
-
Steven S. Myers，2006年11月，他加入我公司董事会并担任薪酬委员会和审计委员会成员以及提名与管理委员会主席。他是SM&A 纳斯达克股票代码：WINS的创立者并在2007年3月退休前担任主席和首席执行官，该公司是全球领先的竞争管理服务供应商。SM&A帮助企业赢得结构化的竞争采购和设计成功建议到项目的过渡。从1982年起，SM&A已经为它的客户成功负责了超过1000个建议，价值超过3.4亿美元。SM&A一贯支持如波音公司（Boeing）、 美国航空航天公司（Lockheed Martin）、埃森哲咨询公司（Accenture）、 雷声公司（Raytheon）、诺斯罗普格鲁曼（Northrop Grumman）、摩托罗拉（Motorola）及其他财富500强企业客户。2008年，SM&A上市。
Steven S. Myers joined the Caladrius Board in November 2006. He graduated from Stanford University with a B.S. in Mathematics. He is a four-time serial entrepreneur, an Ernst & Young "Entrepreneur of the Year" for Software and Information Services, and a recipient of the California Governor's Special Recognition Award.Mr. Myers is the founder, President and Director of his private equity investment company, Dolphin Capital Holdings, Inc., which invests in companies with innovative business strategies. Portfolio investments have included regenerative medicine, biotechnology, medical devices, applied materials development, alternative energy, distressed debt, and for-income real estate. He presently serves as a Director on the board of CEO International Inc., since November 2021. He also served as the Chairman of the LSI Business Development, Inc. board from January 2019 through August 2019. He previously served on the boards of Spikes Security, Inc., QuantumSphere, Inc., the Pacific Council of International Policy and the Bel Air Association. He has conducted business in a dozen countries in Europe and Asia.An Administration policy advisor on Cyber Security, he served in 2012 on the Department of Homeland Security Task Force on Cyber Security Resources and briefed then-DHS Secretary Napolitano on the Task Force recommendations. He was appointed to three terms on the U.S. State Department Advisory Committee on International Economic Policy, which advises the Secretary of State on foreign policy issues. At the Pacific Council on International Policy he serves on the Board of Directors and is Chairman of its National Security Member Committee. - Steven S. Myers，2006年11月，他加入我公司董事会并担任薪酬委员会和审计委员会成员以及提名与管理委员会主席。他是SM&A 纳斯达克股票代码：WINS的创立者并在2007年3月退休前担任主席和首席执行官，该公司是全球领先的竞争管理服务供应商。SM&A帮助企业赢得结构化的竞争采购和设计成功建议到项目的过渡。从1982年起，SM&A已经为它的客户成功负责了超过1000个建议，价值超过3.4亿美元。SM&A一贯支持如波音公司（Boeing）、 美国航空航天公司（Lockheed Martin）、埃森哲咨询公司（Accenture）、 雷声公司（Raytheon）、诺斯罗普格鲁曼（Northrop Grumman）、摩托罗拉（Motorola）及其他财富500强企业客户。2008年，SM&A上市。
- Steven S. Myers joined the Caladrius Board in November 2006. He graduated from Stanford University with a B.S. in Mathematics. He is a four-time serial entrepreneur, an Ernst & Young "Entrepreneur of the Year" for Software and Information Services, and a recipient of the California Governor's Special Recognition Award.Mr. Myers is the founder, President and Director of his private equity investment company, Dolphin Capital Holdings, Inc., which invests in companies with innovative business strategies. Portfolio investments have included regenerative medicine, biotechnology, medical devices, applied materials development, alternative energy, distressed debt, and for-income real estate. He presently serves as a Director on the board of CEO International Inc., since November 2021. He also served as the Chairman of the LSI Business Development, Inc. board from January 2019 through August 2019. He previously served on the boards of Spikes Security, Inc., QuantumSphere, Inc., the Pacific Council of International Policy and the Bel Air Association. He has conducted business in a dozen countries in Europe and Asia.An Administration policy advisor on Cyber Security, he served in 2012 on the Department of Homeland Security Task Force on Cyber Security Resources and briefed then-DHS Secretary Napolitano on the Task Force recommendations. He was appointed to three terms on the U.S. State Department Advisory Committee on International Economic Policy, which advises the Secretary of State on foreign policy issues. At the Pacific Council on International Policy he serves on the Board of Directors and is Chairman of its National Security Member Committee.
- Steven M. Klosk
-
Steven M. Klosk自2008年起担任董事。于1992年加入Cambrex公司，当选Cambrex公司的总裁和行政总裁，于2008年5月成为董事会的一员。在2007年，被任命为Cambrex公司的执行副总裁兼首席营运官，负责制药业务。从2005年至2007年担任制药公司和生物制药事业部的执行副总裁兼首席运营官。1992年至2005年，担任越来越多的要职，包括执行副总裁，负责管理。目前担任NPS（一家私人持有的包装公司）的董事，以及在新泽西州帕特森的圣若瑟医院基金董事会的董事。
Steven M. Klosk joined Cambrex in October 1992 and has served as President and Chief Executive Officer since May 2008. He also became a member of the Board of Directors in May 2008. Mr. Klosk joined the Company as Vice President, Administration. He was appointed Executive Vice President, Administration in October 1996 and was promoted to the position of Executive Vice President, Administration and Chief Operating Officer for the Cambrex Pharma and Biopharmaceutical Business Unit in October 2003. In January 2005 Mr. Klosk assumed direct responsibility for the leadership of the Biopharmaceutical Business Unit as Chief Operating Officer. In August 2006 Mr. Klosk assumed the responsibility of the Pharma business as Executive Vice President and Chief Operating Officer - Biopharma & Pharma and in February 2007 was appointed to Executive Vice President, Chief Operating Officer and President, Pharmaceutical Products and Services. From 1988 until he joined Cambrex, Mr. Klosk was Vice President, Administration and Corporate Secretary for The Genlyte Group, Inc. From 1985 to 1988 he was Vice President, Administration for Lightolier, Inc., a subsidiary of The Genlyte Group, Inc. Mr. Klosk currently serves on the Board of Directors of Caladrius Biosciences, Inc., a publicly traded cell therapy company. - Steven M. Klosk自2008年起担任董事。于1992年加入Cambrex公司，当选Cambrex公司的总裁和行政总裁，于2008年5月成为董事会的一员。在2007年，被任命为Cambrex公司的执行副总裁兼首席营运官，负责制药业务。从2005年至2007年担任制药公司和生物制药事业部的执行副总裁兼首席运营官。1992年至2005年，担任越来越多的要职，包括执行副总裁，负责管理。目前担任NPS（一家私人持有的包装公司）的董事，以及在新泽西州帕特森的圣若瑟医院基金董事会的董事。
- Steven M. Klosk joined Cambrex in October 1992 and has served as President and Chief Executive Officer since May 2008. He also became a member of the Board of Directors in May 2008. Mr. Klosk joined the Company as Vice President, Administration. He was appointed Executive Vice President, Administration in October 1996 and was promoted to the position of Executive Vice President, Administration and Chief Operating Officer for the Cambrex Pharma and Biopharmaceutical Business Unit in October 2003. In January 2005 Mr. Klosk assumed direct responsibility for the leadership of the Biopharmaceutical Business Unit as Chief Operating Officer. In August 2006 Mr. Klosk assumed the responsibility of the Pharma business as Executive Vice President and Chief Operating Officer - Biopharma & Pharma and in February 2007 was appointed to Executive Vice President, Chief Operating Officer and President, Pharmaceutical Products and Services. From 1988 until he joined Cambrex, Mr. Klosk was Vice President, Administration and Corporate Secretary for The Genlyte Group, Inc. From 1985 to 1988 he was Vice President, Administration for Lightolier, Inc., a subsidiary of The Genlyte Group, Inc. Mr. Klosk currently serves on the Board of Directors of Caladrius Biosciences, Inc., a publicly traded cell therapy company.
- Peter G. Traber
-
Peter G. Traber，医学博士，自2009年2月起成为董事。自2011年3月起担任总裁兼首席执行官，现任我们的首席医疗官。自2003年至2008年担任名誉总裁，曾担任贝勒医学院（Baylor College of Medicine）的总裁和首席执行官。从2000年到2003年，他担任GlaxoSmithKline plc。的临床开发和医疗事务高级副总裁兼首席医疗官。现任TerraSep, LLC（加州的生物技术公司）的董事会主席和行政总裁。他还担任过宾夕法尼亚州卫生系统大学（University of Pennsylvania Health System）的行政总裁，宾夕法尼亚医学大学（University of Pennsylvania School of Medicine）的内科消化内科及行政部的主席。从Wayne State School of Medicine获医学博士学位，从密歇根大学获得化学工程学士学位。
Peter G. Traber became President and Chief Executive Officer in March 2011 and is also our Chief Medical Officer. Dr. Traber also served as a director of the Company from 2009 through 2017. Dr. Traber is President Emeritus, and from 2003 to 2008 was President and Chief Executive Officer, of Baylor College of Medicine. From 2000 to 2003 he was Senior Vice President Clinical Development and Medical Affairs and Chief Medical Officer of GlaxoSmithKline plc. Dr. Traber was the Chairman of the Board and Chief Executive Officer of TerraSep, LLC, a Mountain View, CA biotechnology company. He also has served as Chief Executive Officer of the University of Pennsylvania Health System, as well as Chair of the Department of Internal Medicine and Chief of Gastroenterology for the University of Pennsylvania School of Medicine and was named as a director of NeoStem, Inc. Nasdaq:NBS in 2015. Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan. - Peter G. Traber，医学博士，自2009年2月起成为董事。自2011年3月起担任总裁兼首席执行官，现任我们的首席医疗官。自2003年至2008年担任名誉总裁，曾担任贝勒医学院（Baylor College of Medicine）的总裁和首席执行官。从2000年到2003年，他担任GlaxoSmithKline plc。的临床开发和医疗事务高级副总裁兼首席医疗官。现任TerraSep, LLC（加州的生物技术公司）的董事会主席和行政总裁。他还担任过宾夕法尼亚州卫生系统大学（University of Pennsylvania Health System）的行政总裁，宾夕法尼亚医学大学（University of Pennsylvania School of Medicine）的内科消化内科及行政部的主席。从Wayne State School of Medicine获医学博士学位，从密歇根大学获得化学工程学士学位。
- Peter G. Traber became President and Chief Executive Officer in March 2011 and is also our Chief Medical Officer. Dr. Traber also served as a director of the Company from 2009 through 2017. Dr. Traber is President Emeritus, and from 2003 to 2008 was President and Chief Executive Officer, of Baylor College of Medicine. From 2000 to 2003 he was Senior Vice President Clinical Development and Medical Affairs and Chief Medical Officer of GlaxoSmithKline plc. Dr. Traber was the Chairman of the Board and Chief Executive Officer of TerraSep, LLC, a Mountain View, CA biotechnology company. He also has served as Chief Executive Officer of the University of Pennsylvania Health System, as well as Chair of the Department of Internal Medicine and Chief of Gastroenterology for the University of Pennsylvania School of Medicine and was named as a director of NeoStem, Inc. Nasdaq:NBS in 2015. Dr. Traber received his M.D. from Wayne State School of Medicine and a B.S. in chemical engineering from the University of Michigan.
- Michael H. Davidson
-
暂无中文简介
Michael H. Davidson, M.D. Dr. Davidson, a co-founder of Omthera, has served as our Executive Vice President and Chief Medical Officer since December 2008. Since 2007 Dr. Davidson has been a Clinical Professor at the University of Chicago, where he also has served as Director of Preventive Cardiology. Dr. Davidson earned his medical degree from The Ohio State University College of Medicine with residency in internal medicine and fellowship in cardiology at Rush University Medical Center. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and is a Fellow of the American College of Cardiology and the American College of Chest Physicians. He also served as President of the National Lipid Association from 2010 to 2011. From 1987 to 2008 Dr. Davidson was the Founder, President and Chief Executive Officer of the Chicago Center for Clinical Research, currently part of Radiant Research, Inc. An active researcher, Dr. Davidson''s clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids has established him as a key opinion leader in this area. A prolific author and lecturer on lipid disorders, nutrition, and atherosclerosis, Dr. Davidson has coordinated more than 1000 clinical trials in areas of preventive cardiology, published more than 250 articles for leading medical journals and written three books on lipidology. -
暂无中文简介
- Michael H. Davidson, M.D. Dr. Davidson, a co-founder of Omthera, has served as our Executive Vice President and Chief Medical Officer since December 2008. Since 2007 Dr. Davidson has been a Clinical Professor at the University of Chicago, where he also has served as Director of Preventive Cardiology. Dr. Davidson earned his medical degree from The Ohio State University College of Medicine with residency in internal medicine and fellowship in cardiology at Rush University Medical Center. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and is a Fellow of the American College of Cardiology and the American College of Chest Physicians. He also served as President of the National Lipid Association from 2010 to 2011. From 1987 to 2008 Dr. Davidson was the Founder, President and Chief Executive Officer of the Chicago Center for Clinical Research, currently part of Radiant Research, Inc. An active researcher, Dr. Davidson''s clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids has established him as a key opinion leader in this area. A prolific author and lecturer on lipid disorders, nutrition, and atherosclerosis, Dr. Davidson has coordinated more than 1000 clinical trials in areas of preventive cardiology, published more than 250 articles for leading medical journals and written three books on lipidology.
高管简历
中英对照 | 中文 | 英文- Todd C. Girolamo
Todd C. Girolamo于2011年2月加入Caladrius，担任副总法律顾问，并于2015年10月晋升为高级副总裁、总法律顾问和公司秘书。他于1990年在Cahill Gordon & Reindel开始了他的法律职业生涯，后来在Reid & Priest开始了他的法律职业生涯，在证券法、知识产权、就业法和一般商业诉讼领域执业。私人执业后，Girolamo先生在华尔街的机构股票领域工作了12年，担任Oppenheimer & Co.、CIBC World Markets、Leerink Swann & Co.和Summer Street Research Partners的247和63系列持牌负责人，在那里他专门从事股票研究，生物技术、制药和医疗技术市场部门的销售和贸易。Girolamo先生随后担任Lion's Path Capital的分析师和投资组合经理，管理生物制药和医疗技术股票的多空投资组合。Girolamo先生是Longeveron，Inc.董事会的董事，自2022年2月以来一直在该公司任职。Girolamo先生获得了A.B.哈佛大学荣誉学士、宾夕法尼亚大学法学院法学博士和哥伦比亚商学院工商管理硕士。
Todd C. Girolamo joined Caladrius as Associate General Counsel in February 2011 and was promoted to Senior Vice President, General Counsel and Corporate Secretary in October 2015. He began his legal career at Cahill Gordon & Reindel in 1990 and later at Reid & Priest, practicing in the areas of securities law, intellectual property, employment law and general commercial litigation. After private practice, Mr. Girolamo spent 12 years on Wall Street in institutional equities as a Series 24 7 and 63 licensed principal at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Co. and Summer Street Research Partners where he specialized in equity research, sales and trading of biotechnology, pharmaceuticals and medical technology market sectors. Mr. Girolamo then served as an analyst and portfolio manager at Lion's Path Capital managing a long-short portfolio of biopharma and med-tech equities. Mr. Girolamo is a director on the board of Longeveron, Inc., where he has served since February 2022. Mr. Girolamo received an A.B. with honors from Harvard College, a J.D. from the University of Pennsylvania Law School and an M.B.A. from Columbia Business School.- Todd C. Girolamo于2011年2月加入Caladrius，担任副总法律顾问，并于2015年10月晋升为高级副总裁、总法律顾问和公司秘书。他于1990年在Cahill Gordon & Reindel开始了他的法律职业生涯，后来在Reid & Priest开始了他的法律职业生涯，在证券法、知识产权、就业法和一般商业诉讼领域执业。私人执业后，Girolamo先生在华尔街的机构股票领域工作了12年，担任Oppenheimer & Co.、CIBC World Markets、Leerink Swann & Co.和Summer Street Research Partners的247和63系列持牌负责人，在那里他专门从事股票研究，生物技术、制药和医疗技术市场部门的销售和贸易。Girolamo先生随后担任Lion's Path Capital的分析师和投资组合经理，管理生物制药和医疗技术股票的多空投资组合。Girolamo先生是Longeveron，Inc.董事会的董事，自2022年2月以来一直在该公司任职。Girolamo先生获得了A.B.哈佛大学荣誉学士、宾夕法尼亚大学法学院法学博士和哥伦比亚商学院工商管理硕士。
- Todd C. Girolamo joined Caladrius as Associate General Counsel in February 2011 and was promoted to Senior Vice President, General Counsel and Corporate Secretary in October 2015. He began his legal career at Cahill Gordon & Reindel in 1990 and later at Reid & Priest, practicing in the areas of securities law, intellectual property, employment law and general commercial litigation. After private practice, Mr. Girolamo spent 12 years on Wall Street in institutional equities as a Series 24 7 and 63 licensed principal at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Co. and Summer Street Research Partners where he specialized in equity research, sales and trading of biotechnology, pharmaceuticals and medical technology market sectors. Mr. Girolamo then served as an analyst and portfolio manager at Lion's Path Capital managing a long-short portfolio of biopharma and med-tech equities. Mr. Girolamo is a director on the board of Longeveron, Inc., where he has served since February 2022. Mr. Girolamo received an A.B. with honors from Harvard College, a J.D. from the University of Pennsylvania Law School and an M.B.A. from Columbia Business School.
- Kristen K. Buck
Kristen K. Buck于2021年9月加入Caladrius，担任公司研发执行副总裁兼首席医疗官。在加入Caladrius之前，Buck博士于2020年3月至2021年7月在ICON plc工作，担任其首席营销官，代表公司在关键科学、道德和医疗治理事务上的立场，为医疗和科学团体提供指导和监督，并领导药物开发服务小组。在此之前，巴克博士于2018年8月至2020年3月担任Optum Insights（联合医疗保健集团的一部分）的高级副总裁兼临床开发主管，领导数字研究网络（副总裁）临床试验业务的临床运营和监管小组。2014年1月至2018年7月，Buck博士在昆泰/IQVIA担任全球战略药物开发副总裁，为新兴生物技术和大型制药公司设计所有治疗领域的临床开发计划和协议。
Kristen K. Buck joined Caladrius in September 2021 as Executive Vice President of R&D and Chief Medical Officer “CMO” of the Company. Prior to joining Caladrius Dr. Buck worked at ICON plc from March 2020 to July 2021 where she served as its CMO and represented the company's position on key scientific, ethical, and medical governance matters, provided guidance and oversight to the medical and scientific groups, and led the Drug Development Services group. Prior to that, Dr. Buck was Senior Vice President & Chief of Clinical Development at Optum Insights (part of the United Healthcare Group) from August 2018 to March 2020 where she led the clinical operations and regulatory groups within the Digital Research Network (DRN) clinical trial business. From January 2014 to July 2018 Dr. Buck held a position at Quintiles/IQVIA as Vice President of Global Strategic Drug Development designing clinical development plans and protocols across all therapeutic areas for emerging biotech and large pharma.- Kristen K. Buck于2021年9月加入Caladrius，担任公司研发执行副总裁兼首席医疗官。在加入Caladrius之前，Buck博士于2020年3月至2021年7月在ICON plc工作，担任其首席营销官，代表公司在关键科学、道德和医疗治理事务上的立场，为医疗和科学团体提供指导和监督，并领导药物开发服务小组。在此之前，巴克博士于2018年8月至2020年3月担任Optum Insights（联合医疗保健集团的一部分）的高级副总裁兼临床开发主管，领导数字研究网络（副总裁）临床试验业务的临床运营和监管小组。2014年1月至2018年7月，Buck博士在昆泰/IQVIA担任全球战略药物开发副总裁，为新兴生物技术和大型制药公司设计所有治疗领域的临床开发计划和协议。
- Kristen K. Buck joined Caladrius in September 2021 as Executive Vice President of R&D and Chief Medical Officer “CMO” of the Company. Prior to joining Caladrius Dr. Buck worked at ICON plc from March 2020 to July 2021 where she served as its CMO and represented the company's position on key scientific, ethical, and medical governance matters, provided guidance and oversight to the medical and scientific groups, and led the Drug Development Services group. Prior to that, Dr. Buck was Senior Vice President & Chief of Clinical Development at Optum Insights (part of the United Healthcare Group) from August 2018 to March 2020 where she led the clinical operations and regulatory groups within the Digital Research Network (DRN) clinical trial business. From January 2014 to July 2018 Dr. Buck held a position at Quintiles/IQVIA as Vice President of Global Strategic Drug Development designing clinical development plans and protocols across all therapeutic areas for emerging biotech and large pharma.
- David J. Mazzo
David J. Mazzo， 从2008年8月起担任公司CEO和董事会成员。他在制药行业有将近30年经验。2007年3月-2008年4月，他担任terna Zentaris--一家上市国际生物制药公司的总裁、CEO兼董事。2003-2007年，他担任美国Chugai制药公司总裁、CEO兼董事，Chugai是一家生物制药公司，是日本Chugai制药公司的美国子公司。他也担任过研发部高级管理和行政职位，曾是艾塞克斯奇美欧洲子公司先灵葆雅公司董事，先灵葆雅是一家上市制药公司，后被默克公司收购；Hoechst Marion Roussel公司是Hoechst公司的美国子公司，后被赛诺菲制药集团收购，赛诺菲是一家跨国制药公司； Rhone-Poulenc Rorer公司是Rhone-Poulene SA子公司，后者是一家法国制药公司，后来被Hoechst AG公司收购。他目前在pSivida公司--上市生物科技公司的董事会任职，担任非执行董事长；也在Avanir 制药公司--上市生物科技公司的董事会任职。他拥有荣誉项目跨学科人文学士学位和维纳诺瓦大学化学学士学位。另外，他还拥有艾摩斯特马萨诸塞大学化学硕士和分析化学博士学位。他同时也是瑞士洛桑巴黎理工大学的一名研究人员。
David J. Mazzo was appointed as Caladrius' President and Chief Executive Officer on March 28 2017. Dr. Mazzo was previously appointed as Caladrius' Chief Executive Officer and as a member of the Caladrius Board on January 5 2015. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. Nasdaq: RGDO, a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a director of terna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and director of Chugai Pharma USA, LLC, a biopharmaceutical company and U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, that was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, that was subsequently acquired by Hoechst AG. He previously served on the board of directors of publicly held EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.), a biopharmaceutical company, from October 2005 to June 2020 Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA), a therapeutics development company focused on CNS applications that merged with Palisade BIO, from April 2019 to April 2021 and Avanir Pharmaceuticals, Inc., from October 2005 through January 2015 a pharmaceutical company that was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc. (ASX: VTI), a developer and seller of therapeutic contact lenses, where he has served as Chairman of the board since February 2020 and Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents, where he has served on the board since January 2021.Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.David J. Mazzo was appointed as Caladrius' President and Chief Executive Officer on March 28 2017. Dr. Mazzo was previously appointed as Caladrius' Chief Executive Officer and as a member of the Caladrius Board on January 5 2015. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. Nasdaq: RGDO, a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a director of terna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and director of Chugai Pharma USA, LLC, a biopharmaceutical company and U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, that was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, that was subsequently acquired by Hoechst AG. He previously served on the board of directors of publicly held EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.), a biopharmaceutical company, from October 2005 to June 2020 Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA), a therapeutics development company focused on CNS applications that merged with Palisade BIO, from April 2019 to April 2021 and Avanir Pharmaceuticals, Inc., from October 2005 through January 2015 a pharmaceutical company that was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc. (ASX: VTI), a developer and seller of therapeutic contact lenses, where he has served as Chairman of the board since February 2020 and Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents, where he has served on the board since January 2021.Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.- David J. Mazzo， 从2008年8月起担任公司CEO和董事会成员。他在制药行业有将近30年经验。2007年3月-2008年4月，他担任terna Zentaris--一家上市国际生物制药公司的总裁、CEO兼董事。2003-2007年，他担任美国Chugai制药公司总裁、CEO兼董事，Chugai是一家生物制药公司，是日本Chugai制药公司的美国子公司。他也担任过研发部高级管理和行政职位，曾是艾塞克斯奇美欧洲子公司先灵葆雅公司董事，先灵葆雅是一家上市制药公司，后被默克公司收购；Hoechst Marion Roussel公司是Hoechst公司的美国子公司，后被赛诺菲制药集团收购，赛诺菲是一家跨国制药公司； Rhone-Poulenc Rorer公司是Rhone-Poulene SA子公司，后者是一家法国制药公司，后来被Hoechst AG公司收购。他目前在pSivida公司--上市生物科技公司的董事会任职，担任非执行董事长；也在Avanir 制药公司--上市生物科技公司的董事会任职。他拥有荣誉项目跨学科人文学士学位和维纳诺瓦大学化学学士学位。另外，他还拥有艾摩斯特马萨诸塞大学化学硕士和分析化学博士学位。他同时也是瑞士洛桑巴黎理工大学的一名研究人员。
- David J. Mazzo was appointed as Caladrius' President and Chief Executive Officer on March 28 2017. Dr. Mazzo was previously appointed as Caladrius' Chief Executive Officer and as a member of the Caladrius Board on January 5 2015. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. Nasdaq: RGDO, a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a director of terna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and director of Chugai Pharma USA, LLC, a biopharmaceutical company and U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, that was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, that was subsequently acquired by Hoechst AG. He previously served on the board of directors of publicly held EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.), a biopharmaceutical company, from October 2005 to June 2020 Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA), a therapeutics development company focused on CNS applications that merged with Palisade BIO, from April 2019 to April 2021 and Avanir Pharmaceuticals, Inc., from October 2005 through January 2015 a pharmaceutical company that was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc. (ASX: VTI), a developer and seller of therapeutic contact lenses, where he has served as Chairman of the board since February 2020 and Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents, where he has served on the board since January 2021.Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.David J. Mazzo was appointed as Caladrius' President and Chief Executive Officer on March 28 2017. Dr. Mazzo was previously appointed as Caladrius' Chief Executive Officer and as a member of the Caladrius Board on January 5 2015. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. Nasdaq: RGDO, a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a director of terna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and director of Chugai Pharma USA, LLC, a biopharmaceutical company and U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, that was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, that was subsequently acquired by Hoechst AG. He previously served on the board of directors of publicly held EyePoint Pharmaceuticals, Inc. (formerly known as pSivida Corp.), a biopharmaceutical company, from October 2005 to June 2020 Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA), a therapeutics development company focused on CNS applications that merged with Palisade BIO, from April 2019 to April 2021 and Avanir Pharmaceuticals, Inc., from October 2005 through January 2015 a pharmaceutical company that was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc. (ASX: VTI), a developer and seller of therapeutic contact lenses, where he has served as Chairman of the board since February 2020 and Feldan Therapeutics, a private company developing technology for the intracellular delivery of therapeutic agents, where he has served on the board since January 2021.Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.